MATN), a late-stage biotechnology company developing Trabedersen (OT-101), a TGF-β inhibitor with the potential for multiple therapeutic indications including glioblastoma, pancreatic cancer, melanoma and COVID-19, appointed Anthony Maida, III, Ph.D., MA, MBA as Chief Clinical Officer – Translational Medicine for the Company.” data-reactid=”13″Agoura Hills, California, July 07, 2020 (GLOBE NEWSWIRE) — Mateon Therapeutics (MATN), a late-stage biotechnology company developing Trabedersen (OT-101), a TGF-β inhibitor with the potential for multiple therapeutic indications including glioblastoma, pancreatic cancer, melanoma and COVID-19, appointed Anthony Maida, III, Ph.D., MA, MBA as Chief Clinical Officer – Translational Medicine for the Company.
Dr. Maida, a director of the Company since 2015, will retain his position as Board of Director. Dr. Maida is an expert in the clinical development of immuno-oncology and related products. For close to 30 years, Dr. Maida has been involved in all aspects of commercial clinical, preclinical and scientific development of biotherapeutics including translational medicine, protocol design, FDA interactions, manufacturing process validation, and data assessment. He has served in numerous executive and C-suite roles including Chairman, Chief Executive Officer (CEO), Chief Operating Officer (COO), Chief Scientific Officer (CSO), and Chief Financial Officer (CFO) for companies ranging from startups to public companies. Dr. Maida has served on multiple Boards of Directors and Advisory Boards for public and private companies, hedge funds, venture capital and pharma. He is a member of the American Society of Clinical Oncology (ASCO), the American Association for Cancer Research (AACR), the Society of Neuro-Oncology (SNO), the International Society for Biological Therapy of Cancer (iSBTC), and the American Chemical Society (ACS). Prior to graduate school, Dr. Maida was Senior Controller for Lockheed Missile and Space Company, reporting on $1.7 billion in revenue, and Vice President Finance – CFO of Lockheed DataPlan, Inc. Dr. Maida holds a Ph.D. in Immunology (tumor immunology), Master Degree in Toxicology, an MBA and two bachelor degrees (history and biology).
Dr. Maida, commented, “I look forward to driving the clinical development of OT-101 to its eventual approval as therapeutic against COVID-19 and other indications. The Mateon team has done a tremendous job bringing OT-101 to this stage of development and I look forward to working closely with the entire clinical team, our patients, our investigators, and our collaborators.”
Dr. Vuong Trieu, Chief Executive Officer of Mateon said, “We are honored that Dr. Maida has accepted the additional responsibilities within the…